Please assess the completion status of the following clinical trial:

Trial Title: Trisenox® in Women With Metastatic Endometrial Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. ≥18 years of age with histologically confirmed metastatic or recurrent endometrial cancer~2. Documented progression of their endometrial cancer (i.e., within the last 3 months)~3. If of childbearing potential they must agree to use approved barrier methods of contraception~4. Presence of at least one measurable lesion that:~   * Can be accurately measured in at least one dimension with longest diameter ≥20 mm using conventional techniques or ≥10 mm with spiral CT scan (or otherwise at least twice the reconstruction interval for CT or MRI scans).~  * Previously irradiated lesions may be considered to be measurable provided: 1) there has been documented progression of the lesion(s) since completion of radiotherapy, and 2) the criteria for measurability as outlined above are met.~5. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2~6. Minimum life expectancy of 3 months~7. Adequate renal and hepatic function (per study protocol guidelines)~8. Adequate bone marrow function (per study protocol guidelines)~9. Serum cholesterol \<350 mg/dL and triglycerides \< 400 mg/dL~10. Able to understand and give written informed consent~11. Ejection fraction \>55% with no focal left ventricular wall motion abnormalities in patients with a history of coronary artery disease or a history of congestive heart failure.~Exclusion Criteria:~1. Women who are pregnant or lactating~2. Presence of brain metastases~3. Two or more prior cycles of cytotoxic chemotherapy since recurrence (Two total regimens are allowed if one includes adjuvant therapy.)~4. Prior therapy with Trisenox or known sensitivity to this agent~5. Prior anticancer treatment (chemotherapy, radiotherapy, immunotherapy, biological response modifiers, signal transduction inhibitors, etc) within 4 weeks prior to the first dose of Trisenox.~6. Ongoing toxicity associated with prior anticancer therapy (except peripheral neuropathy of ≤ grade 1 by NCI toxicity criteria)~7. Another primary malignancy within the past three years (except for non-melanoma skin cancer and cervical carcinoma in situ)~8. Significant uncontrolled cardiovascular disease~9. Active infection requiring systemic therapy~10. Known HIV infection~11. Treatment with any investigational agent within 4 weeks prior to the first dose of Trisenox~12. Concurrent treatment with immunosuppressive agents other than prescribed corticosteroids~13. Inadequate recovery from any prior surgical procedure or having undergone any major surgical procedure within 2 weeks prior to the first dose of Trisenox~14. Patients having undergone recent placement of a central venous access port will be considered eligible if they have recovered~15. Presence of any other life-threatening illness or organ system dysfunction which, in the opinion of the Investigator, would either compromise the patient's safety or interfere with evaluating the safety of the study drug~16. Prolonged absolute corrected QT interval (QTc) interval \> 500 msec~17. Underlying conduction disease that prevents measurement of QT interval~18. History of ventricular tachycardia or any cardiac arrhythmia requiring the placement of an automated intraventricular cardiac defibrillator.~19. Inability to discontinue therapy with class I or class III antiarrhythmic medications.~20. Inability to discontinue drugs known to be associated with a risk for torsades de pointes

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Trisenox treatment (Type: EXPERIMENTAL): Arsenic trioxide - 0.25 mg/kg/day for 5 consecutive days, every 4 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).